Introduction
Chronic myeloid leukemia (CML) is a clonal multilineage myeloproliferative disorder arising from the neoplastic transformation of a pluripotent hematopoietic stem cell that acquires a unique BCR-ABL fusion oncogene. 1 Clonal dominance is the typical picture seen in the more prevalent final stages of myeloid, erythroid and megakaryocyte maturation, although the stem cell compartment remains predominantly normal throughout chronic phase in most patients. 2 Investigation of the properties of CML stem cells has thus been a major challenge, compounded by a lack of phenotypic properties that enable normal and CML stem cells to be differentially isolated. 3, 4 Xenograft models, particularly those using immunodeficient nonobese diabetic-scid/scid (NOD/SCID) mice, or the even more compromised NOD/SCID-b2microglobulin À/À (NOD/ SCID-b2m À/À ) mice, 5 as recipients offer a potentially valuable approach to the investigation of human leukemic stem cellderived populations and their responses to various treatments in an in vivo setting. 6 However, the predominance of normal stem cells in the marrow of most chronic phase CML patients has resulted in the usual regeneration of mainly normal human cells when chronic phase samples are transplanted into such mice. To circumvent this problem, we identified chronic phase patients whose long-term culture-initiating cells (LTC-ICs) were predominantly leukemic and then assessed the number and types of cells they produced in NOD/SCID and NOD/SCIDb2m À/À mice.
Materials and methods

Patient cells
Low-density cells were isolated by centrifugation on FicollHypaque (Pharmacia, Baie d'Urfe, PQ, Canada) from peripheral blood or leukapheresis (PB) cells, or bone marrow (BM) cells obtained with informed consent from nine adult Ph þ CML patients in chronic phase without any indication of accelerated phase but whose LTC-ICs had been found to be exclusively BCR-ABL/Ph þ (for details of the progenitor content of these samples, see Supplemental Table 1 
RT-PCR and genomic Southern blot analyses
RNA extracts from cells were reverse transcribed and then analyzed for BCR-ABL, interleukin-3 (IL-3) and granulocyte colony-stimulating factor (G-CSF) mRNAs using a nested PCR amplification procedure in which oligo (dT)-based primers and a poly (A) tailing procedure were used in the first step and then a second amplification with specific primers was undertaken. [8] [9] [10] For analyses of genomic BCR-ABL, DNA was extracted from cells, digested, and separated by gel electrophoresis. Membranes were then hybridized with a p17H8 11 and a human BCR probe. 12 The relative intensities of the germline and rearranged BCR bands were determined using a Kodak Digital Science IDt scanner and image software (Eastman Kodak Co., Rochester, NY, USA).
In vitro progenitor assays
Direct colony-forming cell (CFC) assays and 6-week LTC-IC assays using human G-CSF, IL-3 and Steel factor (SF)-producing murine fibroblasts were performed and genotyped by cytogenetic analysis of the colonies produced as previously described. 13, 14 Liquid suspension cultures
þ CD34 þ cells isolated by FACS were cultured at 371C in Iscove's medium containing a serum substitute (BITt, StemCell Technologies), 40 mg/ml of low-density lipoproteins (Sigma Chemicals, St Louis, MO, USA) and 10 À6 mmol 2-mercaptoethanol (Sigma) with or without 20 ng/ml IL-3 (Novartis, Basel, Switzerland), 20 ng/ml IL-6 (Cangene, Mississsauga, ON, Canada), 20 ng/ml G-CSF (StemCell Technologies), 100 ng/ml Flt3-ligand (FL, Immunex Corp., Seattle, WA, USA), and 100 ng/ml SF (prepared in the Terry Fox Laboratory). Viable (trypan blue-excluding) cells were counted using a hemacytometer.
Statistics
Values shown are the mean7s.e.m except where individual data points are given.
Results
Chronic phase CML samples with predominantly leukemic LTC-ICs consistently, rapidly and durably repopulate the BM of immunodeficient mice with leukemic cells
Cells from nine chronic phase CML patients were transplanted into groups of sublethally irradiated NOD/SCID and NOD/ SCID-b2m À/À mice and the number and types of human cells regenerated in the BM of the mice then followed for up to 20 weeks. To increase the likelihood of engraftment with leukemic cells, the samples used were selected from a bank of cryopreserved BM, peripheral blood and leukapheresis harvests on the basis of prior in vitro assays that showed their LTC-IC content to be elevated and exclusively Ph/BCR-ABL þ (see Supplemental Table 1 ). Although there was considerable heterogeneity in the levels of human cells subsequently detected in the BM of the transplanted mice, this could not be attributed to the different types of cell sources used. FACS analysis showed the presence of human CD45/71 þ cells in most recipients of all nine patients' samples ( Figure 1a ). The highest frequencies of human cells were typically seen after 3 weeks (frequently 45% of all cells in the BM). These levels of human cells were confirmed by Southern analysis using a human-specific a-satellite probe ( Figure 2a ). 11 Reblotting with a BCR probe showed that the intensity of the rearranged BCR band was the same as the unrearranged (germline) BCR gene indicating 495% of the human cells present after 3 weeks were leukemic ( Figure 2b ). Subsequently, the proportion of human cells in the BM of the mice usually decreased slightly (to B0.1-5%, levels that are, nevertheless readily detectable, as indicated in Supplemental Figure 1 of the accompanying paper by Chalandon et al 15 ). Thereafter, they remained stable for another 4 months ( Figure 1a ). To determine the proportion of leukemic cells present during this later period, human CD45/71 þ cells were isolated by FACS from representative mice and separately sorted aliquots of 10 3 , 10 2 and 10 cells were analyzed by RT-PCR. These analyses detected BCR-ABL transcripts in all aliquots analyzed (see Figure 3a and Table 1 ) demonstrating the sustained output of CML cells for at least 18 weeks.
At 3 weeks post-transplant, the proportion of human cells in the BM of the CML-transplanted NOD/SCID-b2m À/À mice was, on average, slightly higher (B5-fold) than in the NOD/SCID mice. By 6 weeks, this difference was only B3-fold and thereafter, it disappeared ( Figure 1a ). These differences are Table 1 RT-PCR detection of BCR-ABL, IL-3 and G-CSF transcripts in human cells from mice repopulated with CML cells Features of human CML in xenografted mice W Eisterer et al somewhat lower than those obtained with transplants of normal adult human BM cells (B30-fold higher after 3 weeks and B4-fold higher after 13 weeks in the NOD/SCID-b2m À/À mice, see Table 2 ). 7 The differences obtained with transplants of normal human hematopoietic cells are determined by the relative frequencies in the cells injected of different types of 2) and a third transplanted with cells from patient #16 (lane 3). DNA was digested with BglII and hybridized with a human BCR probe 12 to detect both germline and rearranged BCR sequences. The relative intensities of these two bands were used to calculate the ratios shown below the blot.
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þ CD38 þ and CD34 þ CD38 À short-and long-term repopulating cells that engraft NOD/SCID-b2m À/À and NOD/ SCID mice with different efficiencies. 7 To investigate whether CML cells from patients include analogous phenotypes of transplantable cells, the lin À CD34 þ cells from two CML samples were separated by FACS into their component CD38 þ and CD38
À fractions and then matched proportions of these subsets were injected into NOD/SCID-b2m À/À mice. As shown in Figure 1b , the lin À CD34 þ CD38 þ CML cells from both patients produced an early transient population that was no longer detectable after 6 weeks, whereas the matching CD34 þ CD38 À cells produced more persistent populations. Thus, CML clones also appear to contain subsets of CD34 þ CD38 þ and CD34 þ CD38 À cells with different durabilities of in vivo repopulation.
CML repopulating cells produce an inverted ratio of lympho-myeloid progeny
The lineage representation of the human cells present in the two host genotypes is shown in Figure 1c . At 3 weeks posttransplant, when all of the human cells were BCR-ABL þ , most (on average, B80%) were erythroid (glycophorin A þ , see example in Figure 1d ) in both types of mice. A predominance of erythroid progeny among the cells produced in the first 3 weeks is also a characteristic of normal human short-term repopulating cells.
7 By 6 weeks post-transplant, the human erythroid cells were largely replaced by granulopoietic and lymphoid cells, as occurs with transplants of primitive normal human hematopoietic cells. However, the relative numbers of these two lineages in the CML-transplanted mice were markedly abnormal, with the CML transplants producing mostly granulopoietic (CD33 þ and/ or CD15 þ or CD66b þ ) cells and relatively few B-lymphoid (CD19/20 þ ) cells, whereas the reverse is seen with normal human cells ( Figure 1c and Table 2 ).
Primitive leukemic cells regenerated in immunodeficient mice display an autocrine IL-3/G-CSF phenotype
Human CD34
þ cells were also detectable in the BM of the CML-repopulated mice throughout the period of follow-up and constituted a few percent of all human cells present in both types of host. This pattern is similar to that observed in mice transplanted with normal human BM. 7, 16, 17 In a few mice, sufficient human CD34 þ cells were available for CFC assays to be performed. As shown in Table 3 , early erythroid as well as granulopoietic and occasional multilineage CFCs could be detected in some mice for up to 20 weeks. Genotyping of the colonies produced confirmed their origin from transplanted leukemic cells for two of the three patients tested. RT-PCR analyses of single FACS-sorted CD34 þ human cells (Figure 3b  and Table 1 ) demonstrated a predominance (450%) of leukemic cells in the human CD34 þ cells produced for at least 4 months post-transplant.
Additional RT-PCR analyses performed on the same single human CD34
þ cell extracts showed that human IL-3 and G-CSF transcripts were present in 13 of 14 samples tested ( Table 1 ). The frequency of IL-3-expressing cells in the total human population was low (B1%) relative to their frequency in the regenerated CD34 þ cells (40-50%, Figure 3b and Table 1 ), as is also seen in the cell populations produced in CML patients. 9 The frequency of cells expressing G-CSF was about 10-fold lower than the frequency of cells expressing IL-3. Only BCR-ABL þ cells contained either IL-3 and/or G-CSF transcripts, with G-CSF usually being expressed in a subset of cells that were also expressing IL-3 ( Figure 3b and Table 1 ). To assess the regenerated human CD34
þ cells for functional evidence of factor-independence, additional aliquots were cultured in serum-free medium with and without added growth factors. As illustrated in Figure 3c , growth factor addition stimulated a rapid expansion in the number of viable cells present; but in the absence of added growth factors, a subpopulation of viable cells was also consistently maintained. This is similar to what is seen 
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9,18
Discussion
To develop a consistent xenograft model of human chronic phase CML, we used only patient samples in which all LTC-ICs were BCR-ABL/Ph þ . Transplants of these cells, regardless of their origin from BM, blood or leukapheresis samples, consistently repopulated the BM of both NOD/SCID and NOD/SCIDb2m À/À mice with leukemic (BCR-ABL/Ph þ ) cells for at least 5 months. More prolonged follow-up was precluded because both of these mouse strains develop fatal endogenously derived thymomas between 6 and 12 months of age. 5 Analysis of the cell lineages produced in the mice showed a markedly diminished output of B-lymphoid cells and an associated predominance of granulopoietc cells after 6 weeks. This abnormal pattern of differentiation was accompanied by a continued production of factor-independent, IL-3 and G-CSF-producing BCR-ABL þ
CD34
þ cells. The present studies did not assess the blood or spleens of the mice for evidence of an altered number or distribution of human cells by comparison to what is seen when normal human BM cells are transplanted. This will be of interest in future studies given the mobilized progenitor phenotype typical of patients. However, from the analyses performed, there was no indication of a progressive disease process; for example, continued expansion of the leukemic clone, splenomegaly, hepatomegaly, weight loss or hind limb paralysis, as is typical in mice that are transplanted with cells from patients with acute myeloid or lymphoid leukemia. 19, 20 The indolent behavior of the leukemic clone regenerated in mice transplanted with CML cells is thus more reminiscent of the prolonged latent period of early chronic phase CML 21 or of the very late relapses occasionally seen in CML patients treated with allogeneic transplants. 22 Normal adult mouse BM contains a spectrum of cells with different repopulating activities. These range from cells with rapid but transient myeloid-restricted differentiation potential and limited or no self-renewal capacity 23, 24 to long-term repopulating cells with additional lymphoid differentiation options, delayed activation in vivo and variable abilities for self-renewal. [25] [26] [27] [28] Experiments with xenografted human cells suggest that human hematopoiesis produces an equivalent hierarchy of transplantable cells that are likewise distinguishable by differences in their phenotypes, differentiation potential and their ability to sustain production of differentiated progeny. 7, [29] [30] [31] [32] [33] The present findings suggest that chronic phase CML clones contain a similar hierarchy of primitive transplantable cells. The early wave of myelopoiesis obtained in NOD/SCIDb2m À/À recipients of CML cells appeared enhanced (B5-fold) by comparison to NOD/SCID hosts of the same cells. This is less than the 30-fold difference previously noted when the 3-week output of cells from normal adult human BM cells in NOD/ SCID-b2m À/À and NOD/SCID mice is compared. Moreover, the difference in total human cell output by CML cells transplanted into the two types of mice disappeared rapidly. In contrast, NOD/SCID-b2m À/À mice transplanted with normal adult human BM cells sustain a 4-8-fold higher output of human cells for another 1-2 months. 7, 34 These differences between normal BM and CML transplants suggest corresponding differences in the frequency and/or engrafting efficiency and/or numbers and types of cells produced by very primitive subsets of normal BM and CML cells. Detailed limiting dilution assay and subset characterization experiments will be required to distinguish between these various possibilities. However, it is important to note that primitive CML cells show increased cycling and that only the quiescent subset of these repopulate NOD/SCID mice. 4 Therefore, it is likely that transplantation of NOD/SCID mice with CML cells will also underestimate the number of CML stem cells present in any sample tested.
Another interesting finding was the preservation in the regenerated human CML cells of the same autocrine IL-3/G-CSF phenotype found in primary human CD34 þ cells obtained directly from patients. 9 This demonstrates that neither the activation nor the maintenance of this phenotype is dependent on interactions of CML CD34 þ cells with conditions unique to the BM of patients in whom the disease is likely to have emerged over a period of several years. 21 Rather these results favor the hypothesis that the control of IL-3 and G-CSF expression in BCR-ABL þ hematopoietic progenitors is a direct consequence of their expression of BCR-ABL. Recent studies of BCR-ABLtransduced primitive murine [35] [36] [37] and human 38 hematopoietic cells provide further support for this view.
The present studies have thus set the stage for the use of CMLrepopulated mice to develop quantitative assays for CML stem cells, to identify genetic mechanisms of progression to blast crisis and to evaluate new approaches to the treatment of chronic phase CML in a model that mimics many features of the chronic phase disease in patients.
